Citation Impact
Citing Papers
Risk Factors for Venous Thromboembolism
2003 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Heparin-Protein Interactions
2002 Standout
Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen
2009 Standout
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
2016 Standout
Intracellular degradation of secretion defect‐type mutants of antithrombin is inhibited by proteasomal inhibitors
1997 StandoutNobel
GABAB receptor alterations as indicators of physiological and pharmacological function
2004
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Descending control of pain
2002 Standout
RESTORING FUNCTION AFTER SPINAL CORD INJURY
2003
Spinal-cord injury
2002 Standout
Effect of a selective GABAB receptor agonist baclofen on the μ-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects
2005
REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
2007 Standout
The molecular basis of blood coagulation
1988 Standout
Pain and Spasticity After Spinal Cord Injury
2001
The coagulation cascade: initiation, maintenance, and regulation
1991 Standout
Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature
2005
Purification and characterization of an antithrombin III inactivating enzyme from the venom of the African night adder (Causus rhombeatus)
1992
Reporting standards in venous disease: An update
1995 Standout
Management of Immune Thrombocytopenic Purpura in Adults
2004
Immunoadsorption method using immunoglobulin Adsopak in adult cases with ITP resistant to splenectomy and other medical therapies
2008
Pain following spinal cord injury
2001
Perceived difficulty in dealing with consequences of spinal cord injury
1999
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Immune thrombocytopenic purpura in adults
2007
Protein therapeutics: a summary and pharmacological classification
2007 Standout
The Health and Life Priorities of Individuals with Spinal Cord Injury: A Systematic Review
2012 Standout
Targeting Recovery: Priorities of the Spinal Cord-Injured Population
2004 Standout
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Intrathecal Drug Therapy for Chronic Pain
1999
In vitro and in vivo correlation of clotting protease activity: Effect of heparin
1977
Deficiency of protein C in congenital thrombotic disease.
1981 Standout
Maturation of the hemostatic system during childhood
1992 Standout
Familial Thrombosis Due to Antithrombin III Deficiency
1974
Prostacyclin and Blood Coagulation
1981 StandoutNobel
Serpin Structure, Mechanism, and Function
2002 Standout
Antithrombin III Deficiency and Thromboembolism
1981
Actions and Interactions of Antithrombin and Heparin
1975
Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura
2007
Platelets, Thrombosis and Drugs
1975
Anticoagulant Action of Heparin
1973 Nature
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides
1976 StandoutNobel
GAG Mimetic Libraries: Sulphated Peptide as Heparin-like Glycosaminoglycan Mimics in Their Interaction with FGF-1
2005 StandoutNobel
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Further characterization of the antithrombin-binding sequence in heparin
1982 Standout
Pathogenesis ofHelicobacter pyloriInfection
2006 Standout
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
2012
Partial NH2- and cooh-terminal sequence analyses of Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
Platelet Coagulant Activities and Hemostasis: A Hypothesis
1974
Factor‐Xa Inactivation by Antithrombin III
1973
The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels.
2001
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
2004
RECENT ADVANCES IN PATHOPHYSIOLOGY AND TREATMENT OF SPINAL CORD INJURY
2002
A catalytic role for heparin
1978
Development of Large Scale Fractionation Methods
1979
gamma-aminobutyric acid(B) receptors: first of the functional metabotropic heterodimers.
2000
PLATELET ABNORMALITIES IN VON WILLEBRAND'S DISEASE*
1972
Plasma heparin: a unique, practical, submicrogram-sensitive assay.
1973
The Purification and Mechanism of Action of Human Antithrombin-Heparin Cofactor
1973 Standout
Spinal cord injury rehabilitation research: patient priorities, current deficiencies and potential directions
2010
The molecular-weight-dependence of the anti-coagulant activity of heparin
1978
Human antithrombin III. Carbohydrate components and associated glycolipid.
1978
Platelet Physiology and Abnormalities of Platelet Function
1975 Standout
Inhibition of bovine factor IXa and factor Xa.beta. by antithrombin III
1976
Works of N Akman being referenced
Overview of 321 patients with idiopathic thrombocytopenic purpura
2002
Effects of intrathecal baclofen on chronic spinal cord injury pain
1996
The effect of oestradiol succinate on in vivo platelet adhesion.
1965
Antithrombin III, Antifactor Xa and Heparin
1970